BRPI0717509A2 - sistema de liberação controlada para aplicação nasal de neurotransmissores - Google Patents
sistema de liberação controlada para aplicação nasal de neurotransmissoresInfo
- Publication number
- BRPI0717509A2 BRPI0717509A2 BRPI0717509A BRPI0717509A BRPI0717509A2 BR PI0717509 A2 BRPI0717509 A2 BR PI0717509A2 BR PI0717509 A BRPI0717509 A BR PI0717509A BR PI0717509 A BRPI0717509 A BR PI0717509A BR PI0717509 A2 BRPI0717509 A2 BR PI0717509A2
- Authority
- BR
- Brazil
- Prior art keywords
- nasal
- neurotransmitter
- application
- controlled release
- release system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82810906P | 2006-10-04 | 2006-10-04 | |
PCT/EP2007/008409 WO2008040488A1 (en) | 2006-10-04 | 2007-09-27 | Controlled release delivery system for nasal application of neurotransmitters |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0717509A2 true BRPI0717509A2 (pt) | 2016-05-17 |
BRPI0717509B1 BRPI0717509B1 (pt) | 2019-11-26 |
BRPI0717509B8 BRPI0717509B8 (pt) | 2021-05-25 |
Family
ID=38799348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0717509A BRPI0717509B8 (pt) | 2006-10-04 | 2007-09-27 | sistema de liberação controlada para aplicação nasal de neurotransmissores |
Country Status (20)
Country | Link |
---|---|
US (4) | US20090227550A1 (pt) |
EP (1) | EP2068825B1 (pt) |
JP (1) | JP5248510B2 (pt) |
KR (1) | KR101307133B1 (pt) |
CN (1) | CN101600417B (pt) |
AT (1) | ATE496617T1 (pt) |
AU (1) | AU2007304471B2 (pt) |
BR (1) | BRPI0717509B8 (pt) |
CA (1) | CA2664427C (pt) |
DE (1) | DE602007012276D1 (pt) |
DK (1) | DK2068825T3 (pt) |
ES (1) | ES2358619T3 (pt) |
HK (1) | HK1137658A1 (pt) |
MX (1) | MX2009003654A (pt) |
NO (1) | NO339802B1 (pt) |
PL (1) | PL2068825T3 (pt) |
PT (1) | PT2068825E (pt) |
RU (1) | RU2480208C2 (pt) |
WO (1) | WO2008040488A1 (pt) |
ZA (1) | ZA200902902B (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
DE602007012276D1 (de) | 2006-10-04 | 2011-03-10 | M & P Patent Ag | Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern |
AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
CN109528626A (zh) | 2011-05-13 | 2019-03-29 | 埃瑟尔斯医药有限公司 | 鼻内较低剂量强度睾酮凝胶制剂及其用于治疗性快感缺失病或性欲减退疾患的应用 |
ES2859784T3 (es) | 2011-05-15 | 2021-10-04 | Acerus Biopharma Inc | Formulaciones de gel bioadhesivo de testosterona intranasal y uso de las mismas para tratar el hipogonadismo masculino |
HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
DE102012015248A1 (de) * | 2012-08-05 | 2014-02-06 | Naum Goldstein | Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
JP6597611B2 (ja) * | 2014-07-25 | 2019-10-30 | 日本電気株式会社 | 画像処理装置、監視システム、画像処理方法、及びプログラム |
WO2016018993A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US11903951B2 (en) * | 2016-06-03 | 2024-02-20 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
CN110461340A (zh) * | 2017-01-20 | 2019-11-15 | 马特恩制药股份公司 | 用于降低暴露于空气污染物的风险的鼻用药物组合物 |
CN111902188A (zh) | 2018-01-11 | 2020-11-06 | 马特恩制药股份公司 | 脱髓鞘疾病的治疗 |
WO2019148140A2 (en) * | 2018-01-26 | 2019-08-01 | Wu Joseph C | Implantable biomaterials that enhance stem cell survival and function |
WO2019199704A1 (en) | 2018-04-09 | 2019-10-17 | Katana Pharmaceuticals, Inc. | Oxytocin compositions and methods of use |
CA3097090A1 (en) * | 2018-04-17 | 2019-10-24 | M et P Pharma AG | Compositions and methods for intranasal delivery of pregnenolone |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE943792C (de) | 1949-02-18 | 1956-06-01 | Organon Nv | Verfahren zur Herstellung von injizierbaren Hormonpraeparaten |
GB1032874A (en) | 1964-02-13 | 1966-06-15 | Du Pont | Stabilized polyoxymethylenes |
US3769424A (en) | 1970-10-01 | 1973-10-30 | Merck & Co Inc | Composition and method of treating dopamine deficiency in brain tissue |
US4123417A (en) | 1974-10-10 | 1978-10-31 | Mobil Oil Corporation | Low density polyethylene toughened with ethylene/propylene copolymer |
NL7506407A (nl) | 1975-05-30 | 1976-12-02 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat. |
NL7510104A (nl) | 1975-08-27 | 1977-03-01 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat. |
DE2548413A1 (de) | 1975-10-27 | 1977-04-28 | Schering Ag | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion |
US4315925A (en) | 1980-05-30 | 1982-02-16 | University Of Kentucky Research Foundation | Method of administering natural female sex hormones |
DE3151912A1 (de) | 1981-12-23 | 1983-06-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue ergolin-aminoderivate, verfahren zu ihrer herstellung und deren verwendung als arzneimittel |
US4546882A (en) | 1983-02-07 | 1985-10-15 | American Can Company | Package having oil-containing product |
US4581255A (en) * | 1983-08-30 | 1986-04-08 | Abitibi-Price Corporation | Method of making simulated ceramic tile |
JPS60136283U (ja) | 1984-02-22 | 1985-09-10 | 株式会社シマノ | キヤリバ−ブレ−キ |
US4581225A (en) * | 1984-04-25 | 1986-04-08 | Eli Lilly And Company | Sustained release intranasal formulation and method of use thereof |
ZA852884B (en) * | 1984-04-25 | 1986-11-26 | Lilly Co Eli | Sustained release intranasal formulation and method of use thereof |
US4812448A (en) | 1984-10-22 | 1989-03-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US4752425A (en) | 1986-09-18 | 1988-06-21 | Liposome Technology, Inc. | High-encapsulation liposome processing method |
US4786678A (en) | 1986-12-29 | 1988-11-22 | Mobil Oil Corporation | Method of producing films from polyethylene resin, an additive and a second polymeric resin |
US5049387A (en) | 1987-03-09 | 1991-09-17 | Alza Corporation | Inducing skin tolerance to a sensitizing drug |
US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
JPS646716A (en) | 1987-06-27 | 1989-01-11 | Suzuki Motor Co | Displacement measuring apparatus |
JP2543708B2 (ja) | 1987-07-13 | 1996-10-16 | 旭化成工業株式会社 | 難溶性薬物を封入したエマルジョン製剤の製造方法 |
JPH01160916A (ja) * | 1987-12-18 | 1989-06-23 | Tanabe Seiyaku Co Ltd | ドーパミン経鼻投与製剤 |
NL8801670A (nl) | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
US5397771A (en) | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
US5624960A (en) * | 1991-01-23 | 1997-04-29 | Isis Pharma Gmbh | Orally administrable drugs for the treatment of central dopamine deficiency conditions |
US5500261A (en) | 1991-05-24 | 1996-03-19 | Kao Corporation | Resin composition and a container |
US5221698A (en) | 1991-06-27 | 1993-06-22 | The Regents Of The University Of Michigan | Bioactive composition |
US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
DE4218291A1 (de) | 1992-06-03 | 1993-12-09 | Mattern Et Partner Pharmazeuti | Dosierspray für pernasale Applikation |
SE9301171D0 (sv) | 1993-04-07 | 1993-04-07 | Ab Astra | Pharmaceutical composition containing lipophilic drugs |
CN1091591C (zh) | 1994-02-04 | 2002-10-02 | 利珀克尔集团公司 | 亲脂载体制剂 |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5635203A (en) | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
WO1996011022A1 (fr) | 1994-10-05 | 1996-04-18 | Hisamitsu Pharmaceutical Co., Inc. | Constituants de composition medicamenteuse comprenant des derives de o-toluidine n-substituee et preparation absorbable par voie cutanee |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
US5897894A (en) | 1997-12-29 | 1999-04-27 | General Mills, Inc. | Microwave popcorn with coarse salt crystals and method of preparation |
JP2002513750A (ja) * | 1998-05-07 | 2002-05-14 | エラン コーポレーシヨン ピーエルシー | 溶媒/助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム |
FR2779438B1 (fr) | 1998-06-03 | 2004-12-24 | Jean Marc Aiache | Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant |
GB9823246D0 (en) | 1998-10-24 | 1998-12-16 | Danbiosyst Uk | A nasal drug delivery composition |
US6838091B2 (en) * | 1998-12-18 | 2005-01-04 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6319905B1 (en) * | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
GB9828861D0 (en) * | 1998-12-31 | 1999-02-17 | Danbiosyst Uk | Compositions |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
CZ298573B6 (cs) | 1999-04-01 | 2007-11-14 | N.V. Organon | Farmaceutický prostredek |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
PE20010404A1 (es) | 1999-06-11 | 2001-04-09 | Watson Pharmaceuticals Inc | Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres |
ES2241663T3 (es) | 1999-09-21 | 2005-11-01 | Skyepharma Canada Inc. | Composiciones particuladas modificadas superficialmente de substancias biologicamente activas. |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6231662B1 (en) | 1999-10-25 | 2001-05-15 | George K. Atkinson | Surface treatments for titanium dioxide and other industrial pigments |
AU1261501A (en) | 1999-12-06 | 2001-06-18 | Stanley L. Gore | Compositions and methods for intranasal delivery of active agents to the brain |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US20020072509A1 (en) | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
TW586946B (en) | 2000-12-22 | 2004-05-11 | Novartis Ag | Process to improve stability |
US20020114933A1 (en) | 2000-12-28 | 2002-08-22 | Gould Richard J. | Grease masking packaging materials and methods thereof |
US6730330B2 (en) | 2001-02-14 | 2004-05-04 | Gw Pharma Limited | Pharmaceutical formulations |
EP1383502A4 (en) | 2001-03-06 | 2007-07-25 | Strakan Int Ltd | COMPOUNDS AND METHOD FOR TREATING UROGENITAL DISORDER |
US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
US6833478B2 (en) * | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
US6800363B2 (en) | 2001-08-30 | 2004-10-05 | Toray Plastics, Inc. | Polyolefin oil resistant film using porous particles |
US6815506B2 (en) | 2001-10-15 | 2004-11-09 | Jsr Corporation | Oil-resistant thermoplastic elastomer composition and moldings using the same |
BR0307344A (pt) | 2002-02-01 | 2004-12-14 | Pfizer Prod Inc | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica |
US6855332B2 (en) | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
US6958142B2 (en) | 2002-08-02 | 2005-10-25 | Balance Pharmaceuticals, Inc. | Nasal spray formulation and method |
US7029657B2 (en) | 2002-08-02 | 2006-04-18 | Balance Pharmaceuticals, Inc. | Nasal spray steroid formulation and method |
US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
WO2005065185A2 (en) | 2003-12-24 | 2005-07-21 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
US20070134332A1 (en) * | 2005-11-21 | 2007-06-14 | Medivas, Llc | Polymer particles for delivery of macromolecules and methods of use |
DE602007012276D1 (de) | 2006-10-04 | 2011-03-10 | M & P Patent Ag | Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern |
-
2007
- 2007-09-27 DE DE602007012276T patent/DE602007012276D1/de active Active
- 2007-09-27 PL PL07818492T patent/PL2068825T3/pl unknown
- 2007-09-27 RU RU2009116609/15A patent/RU2480208C2/ru active
- 2007-09-27 AU AU2007304471A patent/AU2007304471B2/en not_active Ceased
- 2007-09-27 ZA ZA200902902A patent/ZA200902902B/xx unknown
- 2007-09-27 KR KR1020097009279A patent/KR101307133B1/ko active IP Right Grant
- 2007-09-27 CA CA2664427A patent/CA2664427C/en active Active
- 2007-09-27 MX MX2009003654A patent/MX2009003654A/es active IP Right Grant
- 2007-09-27 WO PCT/EP2007/008409 patent/WO2008040488A1/en active Application Filing
- 2007-09-27 AT AT07818492T patent/ATE496617T1/de active
- 2007-09-27 DK DK07818492.6T patent/DK2068825T3/da active
- 2007-09-27 EP EP07818492A patent/EP2068825B1/en active Active
- 2007-09-27 CN CN2007800448143A patent/CN101600417B/zh active Active
- 2007-09-27 BR BRPI0717509A patent/BRPI0717509B8/pt active IP Right Grant
- 2007-09-27 ES ES07818492T patent/ES2358619T3/es active Active
- 2007-09-27 PT PT07818492T patent/PT2068825E/pt unknown
- 2007-09-27 JP JP2009530783A patent/JP5248510B2/ja not_active Expired - Fee Related
-
2009
- 2009-04-06 US US12/418,917 patent/US20090227550A1/en not_active Abandoned
- 2009-04-28 NO NO20091695A patent/NO339802B1/no unknown
-
2010
- 2010-03-19 HK HK10102895.0A patent/HK1137658A1/xx not_active IP Right Cessation
-
2011
- 2011-07-30 US US13/194,926 patent/US9186320B2/en active Active
-
2015
- 2015-10-13 US US14/881,332 patent/US9801834B2/en active Active
-
2017
- 2017-09-26 US US15/716,337 patent/US20180200203A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0717509A2 (pt) | sistema de liberação controlada para aplicação nasal de neurotransmissores | |
CR20110110A (es) | Composicion farmaceutica | |
CL2016001809A1 (es) | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15). | |
BR112013012587A2 (pt) | composição farmacêutica para administração nasal | |
BRPI0416370A (pt) | sistema de distribuição de liberação controlada para aplicações nasais | |
BR112015023658A2 (pt) | formulação de vitamina d de liberação modificada, estabilizada e método de administração desta | |
GT200500045A (es) | Solidos supersaturados estabilizados de drogas lipofilicas | |
MX2010009043A (es) | Composicion farmaceutica para farmacos poco solubles. | |
LTPA2019508I1 (lt) | Vaistų pristatymo sistema, skirta sunkiai vandenyje tirpstančių, farmaciškai aktyvių medžiagų, pateikimui | |
BR112012024432A2 (pt) | composição farmacêutica de dissolução rápida | |
MX2014010537A (es) | Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas. | |
MX2015008021A (es) | Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos. | |
CL2011002807A1 (es) | Mezcla farmaceutica comprimible que comprende cristales de un farmaco con tamaño de particulas inferior a 40 um y un adyuvante de la disolucion; procedimiento para preparar un vehiculo de administracion para un farmaco que incluye moler una premezcla de cristales de farmaco y un adyuvante de la disolucion. | |
CL2013002700A1 (es) | Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros | |
EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
MX353623B (es) | Sistema de suministro de farmaco. | |
MD4591C1 (ro) | Dispersie solidă a unui modulator selectiv al receptorului de progesteron | |
BR112018014123A2 (pt) | formulação farmacêutica aquosa estável. | |
WO2009076413A3 (en) | Methods, devices and compositions for controlled drug delivery to injured myocardium | |
BR112014009242A2 (pt) | nanossuspensão farmacêutica | |
MY166972A (en) | Transdermal delivery system containing galantamine or salts thereof | |
BR112015010243A2 (pt) | dispersão sólida, composição para administração oral, composição farmacêutica, e, método para preparar uma dispersão sólida | |
DOP2013000115A (es) | Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartán y método para la preparación de la misma | |
BR112017019364A2 (pt) | dispersões sólidas | |
BR112018012616A2 (pt) | formulação galênica que compreende um fármaco tópico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |